Ocugen Stock Forecast, Price & News

Ocugen's stock was trading at $0.3612 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, OCGN shares have decreased by 22.3% and is now trading at $0.2806.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocugen in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ocugen.

Ocugen is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Ocugen.

Ocugen (NASDAQ:OCGN) issued its quarterly earnings data on Friday, August, 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.16. The business had revenue of $0.04 million for the quarter.
View Ocugen's earnings history.

3 brokers have issued 1-year price objectives for Ocugen's stock. Their forecasts range from $0.70 to $1.25. On average, they expect Ocugen's stock price to reach $0.98 in the next year. This suggests a possible upside of 250.4% from the stock's current price.
View analysts' price targets for Ocugen.

Ocugen saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 6,110,000 shares, an increase of 35.8% from the September 15th total of 4,500,000 shares. Based on an average daily volume of 31,880,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 4.7% of the company's shares are sold short.
View Ocugen's Short Interest.

Some companies that are related to Ocugen include Dyadic International (DYAI), Fennec Pharmaceuticals (FENC), Lineage Cell Therapeutics (LCTX), Cardiff Oncology (TROV), ADMA Biologics (ADMA), LogicBio Therapeutics (LOGC), Lineage Cell Therapeutics (LCTX), DBV TECHNOLOGIE/S (DBVT), Axcella Health (AXLA), Solid Biosciences (SLDB), Ayala Pharmaceuticals (AYLA), BiomX (PHGE), BiomX (PHGE), GENFIT S A/ADR (GNFT) and Applied Genetic Technologies (AGTC).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocugen investors own include Onconova Therapeutics (ONTX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), FuelCell Energy (FCEL), Biocept (BIOC), Opko Health (OPK), Tonix Pharmaceuticals (TNXP), Actinium Pharmaceuticals (ATNM) and Carnival Co. & (CCL).

Ocugen trades on the NASDAQ under the ticker symbol "OCGN."

Ocugen's stock is owned by a number of retail and institutional investors. Top institutional investors include WINTON GROUP Ltd (0.20%). Company insiders that own Ocugen stock include Howard C Draft, Junge Zhang, Kirsten Castillo, Sanjay Subramanian and Shankar Musunuri.
View institutional ownership trends for Ocugen.

OCGN stock was purchased by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd. Company insiders that have bought Ocugen stock in the last two years include Howard C Draft, Junge Zhang, Kirsten Castillo, Sanjay Subramanian, and Shankar Musunuri.
View insider buying and selling activity for Ocugen.

Shares of OCGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OCGN stock can currently be purchased for approximately $0.28.

Ocugen has a market capitalization of $51.39 million. The company earns $-20,240,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis. Ocugen employs 14 workers across the globe.

The official website for Ocugen is ocugen.com.

Ocugen's mailing address is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. The company can be reached via phone at 484-328-4701 or via email at [email protected]